REFERENCES
1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209-49.
2. Lee YT, Wang JJ, Luu M, et al. Comparison of clinical features and outcomes between intrahepatic cholangiocarcinoma and hepatocellular carcinoma in the United States. Hepatology 2021;74:2622-32.
3. Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol 2022;77:1598-606.
4. Chakraborty E, Sarkar D. Emerging therapies for hepatocellular carcinoma (HCC). Cancers 2022;14:2798.
5. Papaconstantinou D, Tsilimigras DI, Pawlik TM. Recurrent hepatocellular carcinoma: patterns, detection, staging and treatment. J Hepatocell Carcinoma 2022;9:947-57.
6. Thylur RP, Roy SK, Shrivastava A, LaVeist TA, Shankar S, Srivastava RK. Assessment of risk factors, and racial and ethnic differences in hepatocellular carcinoma. JGH Open 2020;4:351-9.
7. Teng PC, Huang DQ, Lin TY, Noureddin M, Yang JD. Diabetes and risk of hepatocellular carcinoma in cirrhosis patients with nonalcoholic fatty liver disease. Gut Liver 2023;17:24-33.
8. Devarbhavi H, Asrani SK, Arab JP, et al. Global burden of liver disease: 2023 update. J Hepatol ;2023:S0168-8278(23)00194.
9. Plummer M, de Martel C, Vignat J, et al. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health 2016;4:e609-16.
10. Marengo A, Rosso C, Bugianesi E. Liver cancer: connections with obesity, fatty liver, and cirrhosis. Annu Rev Med 2016;67:103-17.
11. Petrick JL, Florio AA, Znaor A, et al. International trends in hepatocellular carcinoma incidence, 1978-2012. Int J Cancer 2020;147:317-30.
12. Liu Y, Liu L. Changes in the epidemiology of hepatocellular carcinoma in Asia. Cancers 2022;14:4473.
13. Rich NE, Carr C, Yopp AC, Marrero JA, Singal AG. Racial and ethnic disparities in survival among patients with hepatocellular carcinoma in the United States: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2022;20:e267-88.
14. Kronenfeld JP, Ryon EL, Goldberg D, et al. Disparities in presentation at time of hepatocellular carcinoma diagnosis: a United States safety-net collaborative study. Ann Surg Oncol 2021;28:1929-36.
15. Shiels MS, O'Brien TR. Recent decline in hepatocellular carcinoma rates in the United States. Gastroenterology 2020;158:1503-1505.e2.
16. Lee YT, Wang JJ, Luu M, et al. State-level HCC incidence and association with obesity and physical activity in the United States. Hepatology 2021;74:1384-94.
17. Flores YN, Datta GD, Yang L, et al. Disparities in hepatocellular carcinoma incidence, stage, and survival: a large population-based study. Cancer Epidemiol Biomarkers Prev 2021;30:1193-9.
18. Alvarez CS, Petrick JL, Parisi D, et al. Racial/ethnic disparities in hepatocellular carcinoma incidence and mortality rates in the United States, 1992-2018. Hepatology 2022;76:589-98.
19. Chang ET, Keegan TH, Gomez SL, et al. The burden of liver cancer in Asians and Pacific Islanders in the Greater San Francisco Bay Area, 1990 through 2004. Cancer 2007;109:2100-8.
20. Petrick JL, Kelly SP, Altekruse SF, McGlynn KA, Rosenberg PS. Future of hepatocellular carcinoma incidence in the United States forecast through 2030. J Clin Oncol 2016;34:1787-94.
21. Wasley A, Kruszon-Moran D, Kuhnert W, et al. The prevalence of hepatitis B virus infection in the United States in the era of vaccination. J Infect Dis 2010;202:192-201.
22. Han SS, Kelly SP, Li Y, et al. Changing landscape of liver cancer in california: a glimpse into the future of liver cancer in the United States. J Natl Cancer Inst 2019;111:550-6.
23. Camplain R, Teufel-Shone NI, Jiang L, Chang J, Manson SM. Change in physical activity, food choices and hemoglobin A1c among American Indians and Alaska Natives with type 2 diabetes. Prev Med Rep 2022;29:101945.
24. Leston J, Finkbonner J. The need to expand access to hepatitis C virus drugs in the Indian health service. JAMA 2016;316:817-8.
25. McMahon BJ, Bruden D, Townshend-Bulson L, et al. Infection with hepatitis C virus genotype 3 is an independent risk factor for end-stage liver disease, hepatocellular carcinoma, and liver-related death. Clin Gastroenterol Hepatol 2017;15:431-437.e2.
26. Reilley B, Leston J, Hariri S, et al. Birth cohort testing for hepatitis C virus - Indian health service 2012-2015. MMWR Morb Mortal Wkly Rep 2016;65:467-9.
27. Setiawan VW, Wei PC, Hernandez BY, et al. Disparity in liver cancer incidence and chronic liver disease mortality by nativity in hispanics: the multiethnic cohort. Cancer 2016;122:1444-52.
28. Sloane D, Chen H, Howell C. Racial disparity in primary hepatocellular carcinoma: tumor stage at presentation, surgical treatment and survival. J Natl Med Assoc 2006;98:1934-9.
29. Ha J, Yan M, Aguilar M, et al. Race/ethnicity-specific disparities in hepatocellular carcinoma stage at diagnosis and its impact on receipt of curative therapies. J Clin Gastroenterol 2016;50:423-30.
30. Franco RA, Fan Y, Jarosek S, Bae S, Galbraith J. Racial and geographic disparities in hepatocellular carcinoma outcomes. Am J Prev Med 2018;55:S40-8.
31. Dakhoul L, Gawrieh S, Jones KR, et al. Racial disparities in liver transplantation for hepatocellular carcinoma are not explained by differences in comorbidities, liver disease severity, or tumor burden. Hepatol Commun 2019;3:52-62.
32. Yu JR, Wang J, Bhuket T, Liu B, Wong RJ. The impact of ethnic subgroups on tumor stage at diagnosis, treatment received, and long-term survival among Asian adults with hepatocellular carcinoma. J Clin Exp Hepatol 2019;9:182-90.
33. Rich NE, Hester C, Odewole M, et al. Racial and ethnic differences in presentation and outcomes of hepatocellular carcinoma. Clin Gastroenterol Hepatol 2019;17:551-559.e1.
34. Pomenti S, Gandle C, Abu Sbeih H, et al. Hepatocellular carcinoma in hispanic patients: trends and outcomes in a large United States cohort. Hepatol Commun 2020;4:1708-16.
35. Oluyomi AO, Mohammadi KA, El-Serag HB, Thrift AP. Mediating effects of neighborhood-level socioeconomic deprivation on the association between race/ethnicity and advanced hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 2022;31:1402-9.
36. Tan D, Yopp A, Beg MS, Gopal P, Singal AG. Meta-analysis: underutilisation and disparities of treatment among patients with hepatocellular carcinoma in the United States. Aliment Pharmacol Ther 2013;38:703-12.
37. Singal AG, Zhang E, Narasimman M, et al. HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: a meta-analysis. J Hepatol 2022;77:128-39.
38. Zak Y, Rhoads KF, Visser BC. Predictors of surgical intervention for hepatocellular carcinoma: race, socioeconomic status, and hospital type. Arch Surg 2011;146:778-84.
39. Wong RJ, Devaki P, Nguyen L, Cheung R, Nguyen MH. Ethnic disparities and liver transplantation rates in hepatocellular carcinoma patients in the recent era: results from the Surveillance, Epidemiology, and End Results registry. Liver Transpl 2014;20:528-35.
40. Xu L, Kim Y, Spolverato G, Gani F, Pawlik TM. Racial disparities in treatment and survival of patients with hepatocellular carcinoma in the United States. Hepatobiliary Surg Nutr 2016;5:43-52.
41. Scaglione S, Adams W, Caines A, et al. Association between race/ethnicity and insurance status with outcomes in patients with hepatocellular carcinoma. Dig Dis Sci 2020;65:1669-78.
42. Wagle NS, Park S, Washburn D, et al. Racial, ethnic, and socioeconomic disparities in curative treatment receipt and survival in hepatocellular carcinoma. Hepatol Commun 2022;6:1186-97.
43. Ahn JC, Lauzon M, Luu M, et al. Racial and ethnic disparities in early treatment with immunotherapy for advanced HCC in the United States. Hepatology 2022;76:1649-59.
44. Rich NE, John BV, Parikh ND, et al. Hepatocellular carcinoma demonstrates heterogeneous growth patterns in a multicenter cohort of patients with cirrhosis. Hepatology 2020;72:1654-65.
45. Makarova-Rusher OV, Altekruse SF, McNeel TS, et al. Population attributable fractions of risk factors for hepatocellular carcinoma in the United States. Cancer 2016;122:1757-65.
46. Singal AG, Li X, Tiro J, et al. Racial, social, and clinical determinants of hepatocellular carcinoma surveillance. Am J Med 2015;128:90.e1-7.
47. Warnecke RB, Oh A, Breen N, et al. Approaching health disparities from a population perspective: the national institutes of health centers for population health and health disparities. Am J Public Health 2008;98:1608-15.
48. Molinari M, Ayloo S, Tsung A, Samra PB, Jonaissaint N. Adult African Americans undergoing cadaveric liver transplantation for hepatocellular carcinoma within the Milan criteria have the lowest 5-year survival among all the ethnic groups in the United States: analysis of USA national data between January 2002. HR 2018;4:56.
49. Wang Z, Gu X, Thrift AP. Factors associated with favorable survival outcomes for Asians with hepatocellular carcinoma: a sequential matching cohort study. PLoS One 2019;14:e0214721.
50. Jones PD, Scheinberg AR, Muenyi V, et al. Socioeconomic and survival differences among minorities with hepatocellular carcinoma in Florida. J Hepatocell Carcinoma 2019;6:167-81.
51. Welzel TM, Graubard BI, Quraishi S, et al. Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. Am J Gastroenterol 2013;108:1314-21.
52. Ding J, Wen Z. Survival improvement and prognosis for hepatocellular carcinoma: analysis of the SEER database. BMC Cancer 2021;21:1157.
53. Yao J, Liang X, Liu Y, Li S, Zheng M. Trends in incidence and prognostic factors of two subtypes of primary liver cancers: a surveillance, epidemiology, and end results-based population study. Cancer Control 2022;29:10732748211051548.
54. Liu H, Kaltenmeier C, Jonassaint N, et al. The closing survival gap after liver transplantation for hepatocellular carcinoma in the United States. HPB 2022;24:1994-2005.
